Merck & Co., Inc. (NYSE:MRK) is one of the best inexpensive stocks to invest in right now.
Merck & Co., Inc. (NYSE:MRK) announced on May 26 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q3 2026, with payments set to be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026
In a separate development, Merck & Co., Inc. (NYSE:MRK) announced on May 29 that calderasib (MK-1084), in combination with KEYTRUDA®, which is the company’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer with KRAS G12C-mutation and expressing PD-L1. Calderasib is an investigational oral specific KRAS G12C inhibitor, and this marks the first Breakthrough Therapy designation for calderasib, supported by positive data from the Phase 1 KANDLELIT-001 trial.
Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.